Crystal structures of human carboxylesterase 1 in covalent complexes with the chemical warfare agents soman and tabun

Biochemistry

Volumn 46, Issue 17, 2007, Pages 5063-5071

  Fleming, Christopher D ^a   Edwards, Carol C ^b   Kirby, Stephen D ^c   Maxwell, Donald M ^c   Potter, Philip M ^b   Cerasoli, Douglas M ^c   Redinbo, Matthew R ^a  

^a University of North Carolina at Chapel Hill   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN CARBOXYLESTERASE 1; NERVE AGENTS; POISONING; STEREOISOMERS; TOXIC EFFECTS;

ACYLATION; CATALYST POISONING; CRYSTAL STRUCTURE; ORGANOMETALLICS; PHOSPHORUS; TOXICITY;

ENZYMES;

ACETYLCHOLINESTERASE; CARBOXYLESTERASE; CARBOXYLESTERASE 1; CHEMICAL WARFARE AGENT; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; ORGANOPHOSPHORUS COMPOUND; SARIN; SERINE DEHYDRATASE; SOMAN; TABUN; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC TOXICITY; COMPLEX FORMATION; COVALENT BOND; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ENZYME INHIBITION; EXPOSURE; HIGH RISK POPULATION; INTOXICATION; PRIORITY JOURNAL; PROTEIN FAMILY; STEREOISOMERISM; X RAY CRYSTALLOGRAPHY;

CARBOXYLESTERASE; CHEMICAL WARFARE AGENTS; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; PHOSPHORIC ACID ESTERS; SOMAN;

EID: 34247589104     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi700246n     Document Type: Article

References (55)

1. Wiener, S. W., and Hoffman, R. S. (2004) Nerve agents: a comprehensive review, J. Intensive Care Med. 19, 22-37.
2. Newmark, J. (2004) The birth of nerve agent warfare: lessons from Syed Abbas Foroutan, Neurology 62, 1590-1596.
3. Lee, E. C. (2003) Clinical manifestations of sarin nerve gas exposure, JAMA 290, 659-662.
4. Casida, J. E., and Quistad, G. B. (2004) Organophosphate toxicology: safety aspects of nonacetylcholinesterase secondary targets, Chem. Res. Toxicol. 17, 983-998.
5. Kraut, J. (1977) Serine proteases: structure and mechanism of catalysis, Annu. Rev. Biochem. 46, 331-358.
6. Millard, C. B., Kryger, G., Ordentlich, A., Greenblatt, H. M., Harel, M., Raves, M. L., Segall, Y., Barak, D., Shafferman, A., Silman, I., and Sussman, J. L. (1999) Crystal structures of aged phosphonylated acetylcholinesterase: nerve agent reaction products at the atomic level, Biochemistry 38, 7032-7039.
7. Nachon, F., Asojo, O. A., Borgstahl, G. E., Masson, P., and Lockridge, O. (2005) Role of water in aging of human butyrylcholinesterase inhibited by echothiophate: the crystal structure suggests two alternative mechanisms of aging, Biochemistry 44, 1154-1162.
8. Saxena, A., Viragh, C., Frazier, D. S., Kovach, I. M., Maxwell, D. M., Lockridge, O., and Doctor, B. P. (1998) The pH dependence of dealkylation in soman-inhibited cholinesterases and their mutants: further evidence for a push-pull mechanism, Biochemistry 37, 15086-15096.
9. Shafferman, A., Ordentlich, A., Barak, D., Stein, D., Ariel, N., and Velan, B. (1996) Aging of phosphylated human acetylcholinesterase: catalytic processes mediated by aromatic and polar residues of the active centre, Biochem. J. 318 (Part 3), 833-840.
10. Newmark, J. (2004) Therapy for nerve agent poisoning, Arch. Neurol. 61, 649-652.
11. Bajgar, J. (2004) Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment, Adv. Clin. Chem. 38, 151-216.
12. Eyer, P. (2003) The role of oximes in the management of organophosphorus pesticide poisoning, Toxicol. Rev. 22, 165-190.
13. Marrs, T. C. (2004) The role of diazepam in the treatment of nerve agent poisoning in a civilian population, Toxicol. Rev. 23, 145-157.
14. Brown, M. A., and Brix, K. A. (1998) Review of health consequences from high-, intermediate- and low-level exposure to organophosphorus nerve agents, J. Appl. Toxicol. 18, 393-408.
15. Millard, C. B., Lockridge, O., and Broomfield, C. A. (1995) Design and expression of organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase, Biochemistry 34, 15925-15933.
16. Raveh, L., Grunwald, J., Marcus, D., Papier, Y., Cohen, E., and Ashani, Y. (1993) Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization, Biochem. Pharmacol. 45, 2465-2474.
17. Millard, C. B., Lockridge, O., and Broomfield, C. A. (1998) Organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase: synergy results in a somanase, Biochemistry 37, 237-247.
18. Wang, Y., Boeck, A. T., Duysen, E. G., Van Keuren, M., Saunders, T. L., and Lockridge, O. (2004) Resistance to organophosphorus agent toxicity in transgenic mice expressing the G117H mutant of human butyrylcholinesterase, Toxicol. Appl. Pharmacol. 196, 356-366.
19. Raveh, L., Grauer, E., Grunwald, J., Cohen, E., and Ashani, Y. (1997) The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase, Toxicol. Appl. Pharmacol. 145, 43-53.
20. Maxwell, D. M., and Brecht, K. M. (2001) Carboxylesterase: specificity and spontaneous reactivation of an endogenous scavenger for organophosphorus compounds, J. Appl. Toxicol. 21 (Suppl. 1), S103-S107.
21. Maxwell, D. M., Brecht, K. M., Saxena, A., Feaster, S., and Doctor, B. P. (1998) Comparison of Cholinesterases and Carboxylesterase as Bioscavengers for Organophosphorus Compounds, in Structure and Function of Cholinesterases and Related Proteins (Doctor, B. P., Ed.) pp 387-392, Plenum Press, New York.
22. Redinbo, M. R., and Potter, P. M. (2005) Mammalian carboxylesterases: from drug targets to protein therapeutics, Drug Discovery Today 10, 313-325.
23. Satoh, T., and Hosokawa, M. (1998) The mammalian carboxylesterases: from molecules to functions, Annu. Rev. Pharmacol. Toxicol. 38, 257-288.
24. Satoh, T., and Hosokawa, M. (2006) Structure, function and regulation of carboxylesterases, Chem. Biol. Interact. 162, 195-211.
25. Bencharit, S., Edwards, C. C., Morton, C. L., Howard-Williams, E. L., Kuhn, P., Potter, P. M., and Redinbo, M. R. (2006) Multisite promiscuity in the processing of endogenous substrates by human carboxylesterase 1, J. Mol. Biol. 363, 201-214.
26. Bencharit, S., Morton, C. L., Hyatt, J. L., Kuhn, P., Danks, M. K., Potter, P. M., and Redinbo, M. R. (2003) Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition, Chem. Biol. 10, 341-349.
27. Bencharit, S., Morton, C. L., Xue, Y., Potter, P. M., and Redinbo, M. R. (2003) Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme, Nat. Struct. Biol. 10, 349-356.
28. Fleming, C. D., Bencharit, S., Edwards, C. C., Hyatt, J. L., Tsurkan, L., Bai, F., Fraga, C., Morton, C. L., Howard-Williams, E. L., Potter, P. M., and Redinbo, M. R. (2005) Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzyl, J. Mol. Biol. 352, 165-177.
29. Millard, C. B., Koellner, G., Ordentlich, A., Shafferman, A., Silman, I., and Sussman, J. (1999) Reaction products of acetylcholinesterase and VX reveal a mobile histidine in the catalytic triad, J. Am. Chem. Soc. 121, 9883-9884.
30. Danks, M. K., Morton, C. L., Krull, E. J., Cheshire, P. J., Richmond, L. B., Naeve, C. W., Pawlik, C. A., Houghton, P. J., and Potter, P. M. (1999) Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy, Clin. Cancer Res. 5, 917-924.
31. Morton, C. L., and Potter, P. M. (2000) Comparison of Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Spodoptera frugiperda, and COS7 cells for recombinant gene expression. Application to a rabbit liver carboxylesterase, Mol. Biotechnol. 16, 193-202.
32. Otwinowski, Z., and Minor, W. (1997) Processing of X-ray Diffraction Data Collected in Oscillation Mode, in Macromolecular Crystallography, part A (Carter, C., Jr., and Sweet, R., Eds.) pp 307-326, Academic Press, New York.
33. (1994) The CCP4 suite: programs for protein crystallography, Acta Crystallogr. D Biol. Crystallogr. 50, 760-763.
34. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination, Acta Crystallogr. D Biol. Crystallogr. 54, 905-921.
35. Jones, T. A., Zou, J. Y., Cowan, S. W., and Kjeldgaard, M. (1991) Improved methods for building protein models in electron density maps and the location of errors in these models, Acta Crystallogr. A 47 (Part 2), 110-119.
36. Read, R. J. (1986) Improved Fourier Coefficients for maps using phases from partial structures with errors, Acta Crysallogr. A 42, 140-149.
37. Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) PROCHECK: a program to check the stereochemical quality of protein structures, J. Appl. Crystallogr. 26, 283-291.
38. DeLano, W. L. (2002) DeLano Scientific, Palo Alto, CA.
39. Benschop, H. P., Konings, C. A., Van Genderen, J., and De Jong, L. P. (1984) Isolation, anticholinesterase properties, and acute toxicity in mice of the four stereoisomers of the nerve agent soman, Toxicol. Appl. Pharmacol. 72, 61-74.
40. Kim, D. H. (1999) Design of protease inhibitors on the basis of substrate stereospecificity, Biopolymers 51, 3-8.
41. Komiyama, M., and Bender, M. L. (1979) Do cleavages of amides by serine proteases occur through a stepwise pathway involving tetrahedral intermediates?, Proc. Natl. Acad. Sci. U.S.A. 76, 557-560.
42. Ekstrom, F., Akfur, C., Tunemalm, A. K., and Lundberg, S. (2006) Structural changes of phenylalanine 338 and histidine 447 revealed by the crystal structures of tabun-inhibited murine acetylcholinesterase, Biochemistry 45, 74-81.
43. Degenhardt, C. E. A. M., Van Den, Berg, G. R., de Jong, L. P., and Benschop, H. P. (1986) Enantiospecific Complexation Gas Chromotography of Nerve Agents. Isolation and Properties of the Enatiomers of Ethyl N,N- Dimethylphosphoramidocyanidate (tabun), J. Am. Chem. Soc. 108, 8290-8291.
44. Ordentlich, A., Barak, D., Sod-Moriah, G., Kaplan, D., Mizrahi, D., Segall, Y., Kronman, C., Karton, Y., Lazar, A., Marcus, D., Velan, B., and Shafferman, A. (2005) The role of AChE active site gorge in determining stereoselectivity of charged and non-charged VX enantiomers, Chem. Biol. Interact. 157-158, 191-198.
45. Langenberg, J. P., van Dijk, C., Sweeney, R. E., Maxwell, D. M., De Jong, L. P., and Benschop, H. P. (1997) Development of a physiologically based model for the toxicokinetics of C(+/-)P-(+/-)-soman in the atropinized guinea pig, Arch. Toxicol. 71, 320-331.
46. Binkowski, T. A., Naghibzadeh, S., and Liang, J. (2003) CASTp: Computed Atlas of Surface Topography of proteins, Nucleic Acids Res. 31, 3352-3355.
47. Sterri, S. H., and Fonnum, F. (1987) Carboxylesterases in guinea-pig plasma and liver. Tissue specific reactivation by diacetyl-monoxime after soman inhibition in vitro, Biochem. Pharmacol. 36, 3937-3942.
48. Ekstrom, F., Pang, Y. P., Boman, M., Artursson, E., Akfur, C., and Borjegren, S. (2006) Crystal structures of acetylcholinesterase in complex with HI-6, Ortho-7 and obidoxime: structural basis for differences in the ability to reactivate tabun conjugates, Biochem. Pharmacol. 72, 597-607.
49. Lenz, D. E., Yeung, D., Smith, J. R., Sweeney, R. E., Lumley, L. A., and Cerasoli, D. M. (2006) Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: A mini review, Toxicology. DOI: 10.1016.
50. Elhanany, E., Ordentlich, A., Dgany, O., Kaplan, D., Segall, Y., Barak, R., Velan, B., and Shafferman, A. (2001) Resolving pathways of interaction of covalent inhibitors with the active site of acetylcholinesterases: MALDI-TOF/MS analysis of various nerve agent phosphyl adducts, Chem. Res. Toxicol. 14, 912-918.
51. Gopal, S., Rastogi, V., Ashman, W., and Mulbry, W. (2000) Mutagenesis of organophosphorus hydrolase to enhance hydrolysis of the nerve agent VX, Biochem. Biophys. Res. Commun. 279, 516-519.
52. Lockridge, O., Blong, R. M., Masson, P., Froment, M. T., Millard, C. B., and Broomfield, C. A. (1997) A single amino acid substitution, Gly117His, confers phosphotriesterase (organophosphorus acid anhydride hydrolase) activity on human butyrylcholinesterase, Biochemistry 36, 786-795.
53. Cerasoli, D. M., Griffiths, E. M., Doctor, B. P., Saxena, A., Fedorko, J. M., Greig, N. H., Yu, Q. S., Huang, Y., Wilgus, H., Karatzas, C. N., Koplovitz, I., and Lenz, D. E. (2005) In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger, Chem. Biol. Interact. 157-158, 363-365.
54. Grimsley, J. K., Calamini, B., Wild, J. R., and Mesecar, A. D. (2005) Structural and mutational studies of organophosphorus hydrolase reveal a cryptic and functional allosteric-binding site, Arch. Biochem. Biophys. 442, 169-179.
55. Hill, C., Wen-Shan, L., Thoden, J., Holden, H., and Raushel, F. (2003) Enhanced Degredation of Chemical Warfare Agents through Molecular Engineering of the Phosphotriesterase Active Site, J. Am. Chem. Soc. 125, 8990-8991.